Palbociclib Plus Fulvestrant for HR+/HER2- Breast Cancer - 100280

Spotlight
Video

Palbociclib Plus Fulvestrant for HR+/HER2- Breast Cancer

onclivetv has 407 videos Subscribe Here

Loading........
Description: Dr. Verma discusses the PALOMA-3 trial, which examined palbociclib with or without fulvestrant for the treatment of patients with HR-positive, HER2-negative breast cancer.

Sunil Verma, MD, MSEd, FRCPC, medical director, Louise Temerty Breast Cancer Centre at Sunnybrook Health Sciences Centre,
Shared By : onclivetv
Posted on : 07/21/15
Added : 3 years ago
Category : Breast Cancer